ArticleBMC endocrine disorders2026
Association of the serum uric acid/albumin ratio with kidney composite events in patients with type 2 diabetes mellitus: a retrospective cohort study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe serum uric acid-to-albumin ratio (sUAR) has been implicated in various cardiovascular and kidney diseases. However, its association with kidney composite events in patients with type 2 diabetes mellitus (T2DM) remains underexplored. This study aimed to investigate the relationship between sUAR and kidney composite events in T2DM patients.
methodsThis retrospective cohort study included 3,618 patients with T2DM from Chengdu Integrated TCM & Western Medicine Hospital between January 2018 and December 2025. The sUAR was calculated as serum uric acid divided by serum albumin. Participants were categorized into tertiles (T1: 1.99-7.65; T2: 7.66-10.21; T3: 10.22-31.67) based on sUAR. The primary outcome was a composite kidney endpoint, defined as initiation of maintenance dialysis, chronic kidney disease stage 5, or a eGFR decline ≥ 40% from baseline. Multivariable Cox proportional hazards regression, restricted cubic spline (RCS) analysis, Kaplan-Meier curves, subgroup analyses, and SHapley Additive exPlanations (SHAP) were performed to evaluate the association between sUAR and kidney composite events.
resultsDuring a median follow‑up of 28.7 months (IQR: 14.1-52.6), 591 (16.3%) kidney composite events occurred. Compared with the lowest tertile (T1), the highest tertile (T3) of sUAR was associated with a 44% increased risk of kidney composite events after full adjustment (HR = 1.44, 95% CI: 1.12-1.85, P = 0.005). RCS analysis revealed a non-linear relationship between sUAR and kidney composite events. Kaplan-Meier curves demonstrated significant differences in events-free survival across tertiles (log-rank P < 0.001). Subgroup analyses identified age as a significant effect modifier (P < 0.001), with a stronger association observed in younger patients (< 65 years). Among the 22 candidate variables included in the model, sUAR ranked as the sixth most important predictor of kidney composite events, following cystatin C, hemoglobin, albumin, eGFR, and HbA1c.
conclusionsElevated sUAR is independently associated with an increased risk of kidney composite events in patients with T2DM, with a non-linear relationship. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42919291What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.